News and media
News and media
Discover the latest news about motor neurone disease (MND) advocacy and research or visit our one-stop-shop for media,
Media hub.
Got a story to share?
Tell us about how MND has impacted your life.
News List
| 23/03/2017
MNDRIA's Beryl Bayley Postdoctoral Fellow, Dr Michelle Farrar from the University of NSW, is spearheading Australian research into an emerging treatment called nusinersen that has been shown in clinical trials to improve motor development in babies and children with spinal muscular atrophy (SMA), a disease of the motor neurones that most often affects infants. Several Australian infants have participated in these pivotal clinical trials.
| 22/03/2017
Today a joint position paper will be launched by the Neurological Alliance Australia at Parliament House, Canberra to call for equitable and effective support within the NDIS for people with progressive neurodegenerative diseases.
| 7/03/2017
The MND Research Institute of Australia is pleased to announce the recipients of this year’s Susie Harris Travel Fellowship and MNDRIA PhD Scholarship Top Up Grant (2017 - 2019).
| 6/03/2017
A study led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee has found a drug “PMX205” extends the life of mice that have a SOD1 mutation.
| 27/02/2017
Research supported by the MND Research Institute of Australia has led to the discovery of a new and simple test to monitor disease progression in people with MND and evaluate drugs under investigation in MND clinical trials.
| 7/02/2017
The MND Research Institute of Australia is pleased to announce Camille Paynter as the recipient of a co-funded NHMRC/MND Research Institute of Australia Postgraduate Scholarship to start in 2017.
| 22/12/2016
Congratulations to this year’s successful applicants in the annual National Health and Medical Research Council (NHMRC) grant funding round. More than $4 million has been awarded for motor neurone disease (MND) research.
| 22/12/2016
Applicants must be an Australian citizen or have permanent resident status. Applications close at 6 pm EST on Friday 27 January 2017.
| 13/12/2016
A phase II clinical trial led by Dr Michael Benatar from the University of Miami Miller School of Medicine has found a heat shock protein-based therapy shows potential for the treatment of ALS patients with mutations in the SOD1 gene.